drugset / Trial / NCT06608732
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Phase 2
Recruiting
20 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Juventas Cell Therapy Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic leukemia.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inaticabtagene autoleucel | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | Inaticabtagene autoleucel | Cell therapy | 2e+06 cells/kg | Intravenous |